{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:13:58Z","timestamp":1792815238535,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13045-019-0726-5","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T05:38:13Z","timestamp":1556084293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Targeting CLL-1 for acute myeloid leukemia therapy"],"prefix":"10.1186","volume":"12","author":[{"given":"Hongbing","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyer Swaminathan","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simrit","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-9348","authenticated-orcid":false,"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","volume":"129","author":"SR Leong","year":"2017","unstructured":"Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, et al. An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood. 2017;129:609\u201318.","journal-title":"Blood"},{"key":"726_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","volume":"10","author":"C Saygin","year":"2017","unstructured":"Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol. 2017;10:93.","journal-title":"J Hematol Oncol"},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","volume":"10","author":"A Im","year":"2017","unstructured":"Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017;10:94.","journal-title":"J Hematol Oncol"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64:8443\u201350.","journal-title":"Cancer Res"},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-016-0571-x","volume":"16","author":"KS Siveen","year":"2017","unstructured":"Siveen KS, Uddin S, Mohammad RM. Targeting acute myeloid leukemia stem cell signaling by natural products. Mol Cancer. 2017;16:13.","journal-title":"Mol Cancer"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cas.12817","volume":"107","author":"GJ Yoshida","year":"2016","unstructured":"Yoshida GJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci. 2016;107:5\u201311.","journal-title":"Cancer Sci"},{"key":"726_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4252\/wjsc.v6.i4.473","volume":"6","author":"J Zhou","year":"2014","unstructured":"Zhou J, Chng WJ. Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia. World J Stem Cells. 2014;6:473\u201384.","journal-title":"World J Stem Cells"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.4049\/jimmunol.1600011","volume":"197","author":"TJ Hutten","year":"2016","unstructured":"Hutten TJ, Thordardottir S, Fredrix H, Janssen L, Woestenenk R, Tel J, et al. CLEC12A-mediated antigen uptake and cross-presentation by human dendritic cell subsets efficiently boost tumor-reactive T cell responses. J Immunol. 2016;197:2715\u201325.","journal-title":"J Immunol"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/eji.200535628","volume":"36","author":"AS Marshall","year":"2006","unstructured":"Marshall AS, Willment JA, Pyz E, Dennehy KM, Reid DM, Dri P, et al. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur J Immunol. 2006;36:2159\u201369.","journal-title":"Eur J Immunol"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/blood-2005-08-3264","volume":"107","author":"CH Chen","year":"2006","unstructured":"Chen CH, Floyd H, Olson NE, Magaletti D, Li C, Draves K, et al. Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood. 2006;107:1459\u201367.","journal-title":"Blood"},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fimmu.2018.00227","volume":"9","author":"E Chiffoleau","year":"2018","unstructured":"Chiffoleau E. C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front Immunol. 2018;9:227.","journal-title":"Front Immunol"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2013.12.015","volume":"40","author":"K Neumann","year":"2014","unstructured":"Neumann K, Castineiras-Vilarino M, Hockendorf U, Hannesschlager N, Lemeer S, Kupka D, et al. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity. 2014;40:389\u201399.","journal-title":"Immunity"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"14792","DOI":"10.1074\/jbc.M313127200","volume":"279","author":"AS Marshall","year":"2004","unstructured":"Marshall AS, Willment JA, Lin HH, Williams DL, Gordon S, Brown GD. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem. 2004;279:14792\u2013802.","journal-title":"J Biol Chem"},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1172\/JCI0214843","volume":"109","author":"DD Billadeau","year":"2002","unstructured":"Billadeau DD, Leibson PJ. ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest. 2002;109:161\u20138.","journal-title":"J Clin Invest"},{"key":"726_CR15","doi-asserted-by":"publisher","first-page":"57811","DOI":"10.18632\/oncotarget.11063","volume":"7","author":"NH Darwish","year":"2016","unstructured":"Darwish NH, Sudha T, Godugu K, Elbaz O, Abdelghaffar HA, Hassan EE, et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016;7:57811\u201320.","journal-title":"Oncotarget"},{"key":"726_CR16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/ni1417","volume":"7","author":"MJ Robinson","year":"2006","unstructured":"Robinson MJ, Sancho D, Slack EC, LeibundGut-Landmann S, Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol. 2006;7:1258\u201365.","journal-title":"Nat Immunol"},{"key":"726_CR17","doi-asserted-by":"publisher","first-page":"40425","DOI":"10.1074\/jbc.C300225200","volume":"278","author":"H Wu","year":"2003","unstructured":"Wu H, Windmiller DA, Wang L, Backer JM. YXXM motifs in the PDGF-beta receptor serve dual roles as phosphoinositide 3-kinase binding motifs and tyrosine-based endocytic sorting signals. J Biol Chem. 2003;278:40425\u20138.","journal-title":"J Biol Chem"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/0092-8674(93)90404-E","volume":"72","author":"Z Songyang","year":"1993","unstructured":"Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 1993;72:767\u201378.","journal-title":"Cell"},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3324\/haematol.2009.009811","volume":"95","author":"X Zhao","year":"2010","unstructured":"Zhao X, Singh S, Pardoux C, Zhao J, Hsi ED, Abo A, et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica. 2010;95:71\u20138.","journal-title":"Haematologica"},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/ar4250","volume":"15","author":"V Gagne","year":"2013","unstructured":"Gagne V, Marois L, Levesque JM, Galarneau H, Lahoud MH, Caminschi I, et al. Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications. Arthritis Res Ther. 2013;15:R73.","journal-title":"Arthritis Res Ther"},{"key":"726_CR21","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1038\/s41598-017-03027-x","volume":"7","author":"D Sagar","year":"2017","unstructured":"Sagar D, Singh NP, Ginwala R, Huang X, Philip R, Nagarkatti M, et al. Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Sci Rep. 2017;7:2707.","journal-title":"Sci Rep"},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jbspin.2011.12.012","volume":"79","author":"L Michou","year":"2012","unstructured":"Michou L, Cornelis F, Levesque JM, Bombardieri S, Balsa A, Westhovens R, et al. A genetic association study of the CLEC12A gene in rheumatoid arthritis. Joint Bone Spine. 2012;79:451\u20136.","journal-title":"Joint Bone Spine"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/annrheumdis-2014-206644","volume":"75","author":"P Redelinghuys","year":"2016","unstructured":"Redelinghuys P, Whitehead L, Augello A, Drummond RA, Levesque JM, Vautier S, et al. MICL controls inflammation in rheumatoid arthritis. Ann Rheum Dis. 2016;75:1386\u201391.","journal-title":"Ann Rheum Dis"},{"key":"726_CR24","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.celrep.2015.05.045","volume":"11","author":"J Begun","year":"2015","unstructured":"Begun J, Lassen KG, Jijon HB, Baxt LA, Goel G, Heath RJ, et al. Integrated genomics of Crohn's disease risk variant identifies a role for CLEC12A in antibacterial autophagy. Cell Rep. 2015;11:1905\u201318.","journal-title":"Cell Rep"},{"key":"726_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3389\/fimmu.2018.00804","volume":"9","author":"C Fresno Del","year":"2018","unstructured":"Del Fresno C, Iborra S, Saz-Leal P, Martinez-Lopez M, Sancho D. Flexible signaling of myeloid C-type lectin receptors in immunity and inflammation. Front Immunol. 2018;9:804.","journal-title":"Front Immunol"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/cmi.12249","volume":"16","author":"JC Hoving","year":"2014","unstructured":"Hoving JC, Wilson GJ, Brown GD. Signalling C-type lectin receptors, microbial recognition and immunity. Cell Microbiol. 2014;16:185\u201394.","journal-title":"Cell Microbiol"},{"key":"726_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/eji.200738057","volume":"38","author":"E Pyz","year":"2008","unstructured":"Pyz E, Huysamen C, Marshall AS, Gordon S, Taylor PR, Brown GD. Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand. Eur J Immunol. 2008;38:1157\u201363.","journal-title":"Eur J Immunol"},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11:7.","journal-title":"J Hematol Oncol"},{"key":"726_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/cyto.b.21540","volume":"94","author":"M Toft-Petersen","year":"2018","unstructured":"Toft-Petersen M, Stidsholt Roug A, Plesner T, Ebbesen L, Brown GD, Nederby L. The CLEC12A receptor marks human basophils: potential implications for minimal residual disease detection in acute myeloid leukemia. Cytometry B Clin Cytom. 2018;94:520\u20136.","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"726_CR30","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/jcmm.13519","volume":"22","author":"Marie Bill","year":"2018","unstructured":"Bill M, BvKN P, P SW, Laine Herborg L, Stidsholt Roug A, Hokland P, et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J Cell Mol Med. 2018;22(4):2311-8.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"726_CR31","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","volume":"25","author":"H Tashiro","year":"2017","unstructured":"Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther. 2017;25:2202\u201313.","journal-title":"Mol Ther"},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A Rhenen van","year":"2007","unstructured":"van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659\u201366.","journal-title":"Blood"},{"key":"726_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cyto.b.20614","volume":"82","author":"HO Larsen","year":"2012","unstructured":"Larsen HO, Roug AS, Just T, Brown GD, Hokland P. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom. 2012;82:3\u20138.","journal-title":"Cytometry B Clin Cytom"},{"key":"726_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/hon.2352","volume":"35","author":"DS Eissa","year":"2017","unstructured":"Eissa DS, Kandeel EZ, Ghareeb M. Human myeloid inhibitory C-lectin: a highly specific and stable acute myeloid leukemia marker. Hematol Oncol. 2017;35:814\u201320.","journal-title":"Hematol Oncol"},{"key":"726_CR35","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Song G, Shurtleff S, Yeoh AE, Chng WJ, Chen SP, et al. Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight. 2018;3(9): e98561.","DOI":"10.1172\/jci.insight.98561"},{"key":"726_CR36","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","volume":"21","author":"A Rhenen van","year":"2007","unstructured":"van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21:1700\u20137.","journal-title":"Leukemia"},{"key":"726_CR37","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","volume":"11","author":"A Rhenen van","year":"2005","unstructured":"van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520\u20137.","journal-title":"Clin Cancer Res"},{"key":"726_CR38","doi-asserted-by":"publisher","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","volume":"9","author":"M Terwijn","year":"2014","unstructured":"Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587.","journal-title":"PLoS One"},{"key":"726_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.12614","volume":"164","author":"AS Roug","year":"2014","unstructured":"Roug AS, Larsen HO, Nederby L, Just T, Brown G, Nyvold CG, et al. hMICL and CD123 in combination with a CD45\/CD34\/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia. Br J Haematol. 2014;164:212\u201322.","journal-title":"Br J Haematol"},{"key":"726_CR40","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1309\/AJCPN4G1IZPABRLH","volume":"137","author":"AM Harrington","year":"2012","unstructured":"Harrington AM, Olteanu H, Kroft SH. A dissection of the CD45\/side scatter \u201cblast gate\u201d. Am J Clin Pathol. 2012;137:800\u20134.","journal-title":"Am J Clin Pathol"},{"key":"726_CR41","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","volume":"25","author":"B Zheng","year":"2019","unstructured":"Zheng B, Yu SF, Del Rosario G, Leong SR, Lee GY, Vij R, et al. An anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia. Clin Cancer Res. 2019;25:1358\u201368.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"726_CR42","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1080\/19420862.2018.1517565","volume":"10","author":"Douglas D. Leipold","year":"2018","unstructured":"Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, et al. Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: an antibody-drug conjugate for the treatment of acute myeloid leukemia. MAbs. 2018;10(8):1312-21.","journal-title":"mAbs"},{"key":"726_CR43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","volume":"2","author":"YP Jiang","year":"2018","unstructured":"Jiang YP, Liu BY, Zheng Q, Panuganti S, Chen R, Zhu J, et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018;2:1738\u201349.","journal-title":"Blood Adv"},{"key":"726_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/19420862.2015.1007811","volume":"7","author":"VR Wiersma","year":"2015","unstructured":"Wiersma VR, de Bruyn M, Shi C, Gooden MJ, Wouters MC. Samplonius DF, et al. . C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs. 2015;7:321\u201330.","journal-title":"MAbs"},{"key":"726_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8:104.","journal-title":"J Hematol Oncol"},{"key":"726_CR46","doi-asserted-by":"publisher","first-page":"9841","DOI":"10.1002\/anie.201405353","volume":"53","author":"H Lu","year":"2014","unstructured":"Lu H, Zhou Q, Deshmukh V, Phull H, Ma J, Tardif V, et al. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl. 2014;53:9841\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"key":"726_CR47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V126.23.325.325","volume":"126","author":"PFVDR Loo","year":"2015","unstructured":"Loo PFVDR, Dolstra H, Shamsili S, Bakker L. Preclinical evaluation of MCLA117, a CLEC12AxCD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML. blood. 2015;126:325.","journal-title":"blood"},{"key":"726_CR48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.molimm.2016.12.010","volume":"81","author":"C Macri","year":"2017","unstructured":"Macri C, Dumont C, Panozza S, Lahoud MH, Caminschi I, Villadangos JA, et al. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes. Mol Immunol. 2017;81:143\u201350.","journal-title":"Mol Immunol"},{"key":"726_CR49","doi-asserted-by":"publisher","first-page":"7587","DOI":"10.4049\/jimmunol.0900464","volume":"182","author":"MH Lahoud","year":"2009","unstructured":"Lahoud MH, Proietto AI, Ahmet F, Kitsoulis S, Eidsmo L, Wu L, et al. The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol. 2009;182:7587\u201394.","journal-title":"J Immunol"},{"issue":"11","key":"726_CR50","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3390\/ijms18112259","volume":"18","author":"Eduardo Laborda","year":"2017","unstructured":"Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, et al. Development of a chimeric antigen receptor targeting C-type lectin-like Molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 2017;18(11):2259.","journal-title":"International Journal of Molecular Sciences"},{"key":"726_CR51","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V128.22.766.766","volume":"128","author":"SSRM Kenderian","year":"2016","unstructured":"Kenderian SSRM, Shestova O, Klichinsky M, Kim MY, Soderquist C, Bagg A, Singh R, Richardson C, Young RM, June CH, Gill SI. Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. Blood. 2016;128:766.","journal-title":"Blood"},{"issue":"Suppl 1","key":"726_CR52","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2018-99-113438","volume":"132","author":"EDKM Togni","year":"2018","unstructured":"Togni EDKM, Cooper ML, Ritchey J, O'Neal J, Niswonger J, DiPersio JF. Chimeric antigen receptor T cells specific for CLL-1 for treatment of acute myeloid leukemia. Blood. 2018;132(Suppl 1):2205.","journal-title":"Blood"},{"key":"726_CR53","unstructured":"Liu F, Pinz K, Ma Y, Wada M, Chen K, Ma G, et al. First-in-human CLL1-CD33 compound CAR T cells as a two-pronged approach for the treatment of refractory acute myeloid leukemia. HemaSphere. 2018;2(S1):29."},{"issue":"Suppl 1","key":"726_CR54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, et al. First-in-human CLL1-CD33 compound CAR-T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132(Suppl 1):901.","journal-title":"Blood"},{"key":"726_CR55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","volume":"11","author":"J Zhao","year":"2018","unstructured":"Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11:132.","journal-title":"J Hematol Oncol"},{"key":"726_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22.","journal-title":"Biomark Res"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0726-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0726-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0726-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T23:09:28Z","timestamp":1587596968000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0726-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0726-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"4 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"41"}}